IP Library Granted Patent US 11,111,283
Granted Patent B2
US 11,111,283 · App. 16/270,371 · Granted Sep 7, 2021

Peptides and compositions for treatment of joint damage

Inventors: Kristen Johnson (San Diego, CA); Jian Shi (San Diego, CA)
Assignee: NOVARTIS AG
C07K14/515A61K31/728A61K35/32A61K38/1709A61K38/1891A61K38/385A61K38/45A61K45/06A61P19/02C07K14/47C12N5/0655C12N15/00C12N15/11C12N15/63C12Q1/6883G01N33/6887A61K38/00C07K2319/30C12N2501/17C12N2506/1346C12Q2600/118C12Q2600/158G01N2333/78G01N2800/105G01N2800/52Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,111,283
App. No.
16/270,371
Granted
Sep 7, 2021
Kind
B2
Abstract

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

Claims (13)

1. An isolated polynucleotide encoding a polypeptide having at least 95% amino acid sequence identity to a polypeptide consisting of the amino acid sequence set forth as SEQ ID NO: 28, wherein the polypeptide comprises an amino acid that is a polar amino acid other than K or R at position 423 as determined with reference to SEQ ID NO:1, and wherein the polypeptide has chondrogenic activity.

2. The isolated polynucleotide according to claim 1 , which is complementary DNA (cDNA) or messenger RNA (mRNA).

3. The isolated polynucleotide according to claim 1 , wherein the encoded polypeptide further comprises a secretion signal sequence.

4. The isolated polynucleotide according to claim 1 , wherein the encoded polypeptide further comprises a fusion domain selected from the group consisting of a polyhistidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, an immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), a human serum albumin (HSA), a FLAG tag, influenza virus haemagglutinin (HA), and a c-myc tag.

5. The isolated polynucleotide according to claim 1 , which is codon-optimized for expression in a host cell.

6. The isolated polynucleotide according to claim 1 , which is operably linked to a promoter or other regulatory sequence.

7. A cloning or expression vector comprising one or more polynucleotides according to claim 1 , wherein the vector is suitable for the recombinant production of the encoded polypeptide.

8. A host cell, comprising one or more cloning or expression vectors according to claim 7 .

9. The host cell of claim 8 , which is a mammalian host cell, a bacterial host cell, a yeast host cell, or an insect host cell.

10. A process for the production of a polypeptide, comprising culturing a host cell according to claim 9 under conditions sufficient to express the polypeptide, and thereafter purifying and recovering the polypeptide from the host cell culture.

11. A kit comprising the polynucleotide according to claim 1 , wherein the kit comprises: a first container comprising the polynucleotide; and a second container having an aqueous reconstitution formula.

12. The kit according to claim 11 , wherein one container comprises a single chambered pre-filled syringe.

13. The kit according to claim 11 , wherein the containers are encompassed as a multi-chambered pre-filled syringe.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2020
From: JOHNSON, KRISTEN; SHI, JIAN
To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF)
Reel/Frame 052314/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2020
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF)
To: IRM LLC
Reel/Frame 052314/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2020
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF)
To: IRM LLC
Reel/Frame 052314/0577 →
MERGER AND CHANGE OF NAME Recorded Apr 4, 2020
From: IRM LLC; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD
Reel/Frame 052314/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2020
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD
To: NOVARTIS AG
Reel/Frame 052314/0585 →
Continuity (6)
Continuation 15660914 · Jul 26, 2017
Division 15212702 · Jul 18, 2016
Continuation 15052029 · Feb 24, 2016
Division 14201694 · Mar 7, 2014
Provisional Application 61775400 · Mar 8, 2013
Related Publication 20190161527A1 · May 30, 2019